
Nivolumab Plus Ipilimumab Receives EC Approval for First-Line Unresectable HCC
The European Commission (EC) has approved nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for the frontline treatment of adult patients with unresectable or advanced hepatocellular carcinoma (HCC).1 The regulatory decision was supported by …